SAN FRANCISCO--(BUSINESS WIRE)--SARcode Corporation, a privately-held biopharmaceutical company focused on developing small molecule LFA-1 antagonists to treat inflammatory diseases, today announced the completion of a Phase 1 study of the safety, tolerability, and pharmacokinetics of its lead molecule, SAR 1118 in healthy human subjects. The full set of Phase 1 data is anticipated to be presented at a major ophthalmology meeting in the spring of 2009.
